Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

This study tests a new type of immune cell therapy — called CIML NK cell therapy — given early (preemptively) after a stem cell transplant to patients with certain blood cancers who are at high risk of the cancer coming back. NK cells are a type of immune cell that naturally attacks cancer. **You may be eligible if...** - You have AML (acute myeloid leukemia), MDS (a pre-leukemia condition), or MDS/MPN overlap syndrome that is at high risk of relapse after transplant - You have had a blood stem cell transplant - You had measurable disease before the transplant (with some exceptions) - Your cancer falls into specific high-risk categories as defined by the study protocol **You may NOT be eligible if...** - Your cancer is not one of the qualifying types (AML, MDS, or MDS/MPN) - Your risk of relapse is not considered high by the study criteria - You do not meet organ function and blood count requirements after transplant Talk to your doctor to see if this trial is right for you.